{"id":34418,"date":"2026-01-29T17:55:46","date_gmt":"2026-01-29T12:25:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34418"},"modified":"2026-01-29T17:55:47","modified_gmt":"2026-01-29T12:25:47","slug":"medtech-news-for-seno-medical-spine-innovation-laborie","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie","title":{"rendered":"Seno Medical Secures EU MDR CE Mark for Next-Generation Imagio\u00ae Imaging System; Spine Innovation Announces FDA 510(k) Clearance of LOGIC\u2122 Titanium Expandable Interbody System; Laborie Adds JADA\u00ae System to Obstetrics Portfolio for Rapid PPH Control; Olympus Introduces SecureFlex\u2122 Single-Use Fine Needle Biopsy Device in the U.S.; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; Myra Vision Begins U.S. ADAPT Glaucoma Study, Treating First Participant"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a312310b01f0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a312310b01f0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\/#Seno_Medicals_Next-Generation_Imagio%C2%AE_Imaging_System_Obtained_European_Union_EU_Medical_Device_Regulation_MDR_CE_Mark_Certification\" >Seno Medical\u2019s Next-Generation Imagio\u00ae Imaging System Obtained European Union (EU) Medical Device Regulation (MDR) CE Mark Certification&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\/#Spine_Innovation_Announced_the_FDA_510k_Clearance_for_LOGIC%E2%84%A2_Titanium_Expandable_Interbody_System\" >Spine Innovation Announced the FDA 510(k) Clearance for LOGIC\u2122 Titanium Expandable Interbody System&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\/#Laborie_Acquired_the_JADA%C2%AE_System_for_Rapid_Postpartum_Hemorrhage_Control_Expanding_Obstetrics_Portfolio\" >Laborie Acquired the JADA\u00ae System for Rapid Postpartum Hemorrhage Control, Expanding Obstetrics Portfolio&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\/#Olympus_Announced_US_Launch_of_the_SecureFlex%E2%84%A2_Single-Use_Fine_Needle_Biopsy_Device\" >Olympus Announced U.S. Launch of the SecureFlex\u2122 Single-Use Fine Needle Biopsy Device<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\/#Kardium_Announced_Publication_of_PULSAR_Pivotal_Trial_Results_in_JACC\" >Kardium Announced Publication of PULSAR Pivotal Trial Results in JACC&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\/#First_Patient_Treated_in_Myra_Visions_US_ADAPT_Clinical_Study_for_Glaucoma\" >First Patient Treated in Myra Vision\u2019s U.S. ADAPT Clinical Study for Glaucoma&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-seno-medical-s-next-generation-imagio-imaging-system-obtained-european-union-eu-medical-device-regulation-mdr-ce-mark-certification-nbsp\"><span class=\"ez-toc-section\" id=\"Seno_Medicals_Next-Generation_Imagio%C2%AE_Imaging_System_Obtained_European_Union_EU_Medical_Device_Regulation_MDR_CE_Mark_Certification\"><\/span><strong>Seno Medical\u2019s Next-Generation Imagio\u00ae Imaging System Obtained European Union (EU) Medical Device Regulation (MDR) CE Mark Certification&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On January 26, 2026, Seno Medical received CE Mark certification for its next-generation Imagio\u00ae Imaging System, Model 9100, confirming that the device met the stringent safety, performance, and quality requirements set under the EU MDR framework and assessed by EU-approved notified bodies. This certification, which is mandatory for commercialization in the European Union and other regions recognizing CE Mark standards, enabled broader market access for the system. The Imagio\u00ae System was designed to help physicians and healthcare facilities differentiate between benign and malignant breast lesions by using a novel combination of artificial intelligence (SenoGram\u00ae), ultrasound, and opto-acoustic imaging technology, supporting clinical decisions on whether invasive diagnostic procedures were necessary. Seno Medical had previously received its first CE Mark under the Medical Device Directive (MDD) in 2014, and the Model 9100 represented a market-optimized update, incorporating state-of-the-art opto-acoustic imaging capabilities and native AI-driven clinical decision support.<\/p>\n\n\n\n<p>The Imagio\u00ae technology combined light, sound, and artificial intelligence to generate diagnostic information previously unavailable from conventional imaging modalities. Opto-acoustic imaging served as a novel medical imaging approach by integrating functional, anatomic, and morphologic data via laser-based optics and sound waves, and proprietary AI algorithms to produce high-resolution, high-contrast images with decision-support insights for clinicians. The system delivered a non-invasive diagnostic solution that did not rely on ionizing radiation, contrast agents, breast compression, or limitations on patient body habitus, as seen with MRI. It provided real-time imaging and same-day results, improving workflow efficiency in diagnostic centers while reducing patient stress and anxiety. The system was indicated for use by trained and qualified healthcare providers to evaluate palpable and non-palpable breast abnormalities in adult patients referred for diagnostic breast imaging following clinical findings or prior examinations such as screening mammography.<\/p>\n\n\n\n<p><em>\u201cEU MDR certification is one of the most challenging regulatory processes, and we are so pleased to have achieved this significant milestone for our most recent version of the Imagio\u00ae System,\u201d commented Tom Umbel, CEO of Seno Medical. \u201cImagio\u00ae delivers a revolutionary leap forward in patient care, and we are thrilled to be able to collaborate with our European colleagues to improve diagnostic processes for providers and patients.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/diagnostic-imaging-equipment-market\"><strong>Diagnostic Imaging Equipment Market Report<\/strong><\/a>,\u201d the global diagnostic imaging equipment market was valued at <strong>USD 24.15 billion<\/strong> in 2020 and is projected to grow at a <strong>CAGR of 5.10%<\/strong> from 2024 to 2030, reaching <strong>USD 33.56 billion<\/strong>. The demand for Diagnostic Imaging Equipment is primarily driven by rising technological advancements, the growing burden of chronic diseases, increasing patient awareness of early-stage diagnosis, the need for effective &amp; efficient imaging technologies for diagnosis, and an aging population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-spine-innovation-announced-the-fda-510-k-clearance-for-logic-titanium-expandable-interbody-system-nbsp\"><span class=\"ez-toc-section\" id=\"Spine_Innovation_Announced_the_FDA_510k_Clearance_for_LOGIC%E2%84%A2_Titanium_Expandable_Interbody_System\"><\/span><strong>Spine Innovation Announced the FDA 510(k) Clearance for LOGIC\u2122 Titanium Expandable Interbody System&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On January 26, 2026, Spine Innovation, LLC, a medical device startup focused on developing novel interbody fusion implants, announced that it had received FDA 510(k) clearance to market the LOGIC\u2122 Titanium Implant System. The LOGIC\u2122 Implant System represented the next-generation version of the LOGIC\u2122 platform and incorporated OsteoSync\u2122 Ti, a patented pure titanium lattice material developed by Sites Medical that had been implanted in more than 250,000 patients since 2014.<\/p>\n\n\n\n<p>The patented LOGIC\u2122 implant was designed with a reduced profile during implantation and expanded to more than double its size once deployed, providing enhanced stability and increased bone graft volume. This expandable design had been used successfully in the U.S. for approximately 10 years and had previously been manufactured from polyether ether ketone (PEEK). The implant restored disc height and sagittal balance while resisting subsidence and expulsion, supported by an expanded footprint of 18 mm \u00d7 26 mm that spanned the vertebral body. With the FDA clearance, the LOGIC\u2122 implant became available in the OsteoSync\u2122 Ti material, offering advanced structural support and improved bone integration.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-fusion-devices-market\"><strong>Spinal Fusion Devices Market Report<\/strong><\/a>,\u201d the spinal fusion devices market was valued at <strong>USD 7,139.71 million<\/strong> in 2024, growing at a <strong>CAGR of 5.31% <\/strong>during the forecast period from 2025 to 2032 to reach <strong>USD 10,762.88 million<\/strong> by 2032. The spinal fusion devices market is experiencing steady growth, driven by the rising instances of spinal disorders along with the growing global prevalence of chronic pain. Additionally, conditions such as degenerative disc disease, spondylolisthesis, and spinal stenosis are becoming increasingly common, particularly among the aging population. The surge in road traffic accidents further highlights the urgent need for effective spinal fusion solutions to restore mobility and reduce long-term disability. Additionally, the increase in product development activities among key market players is further driving the overall market for spinal fusion devices. Collectively, these factors are anticipated to fuel the expansion of the spinal fusion devices market over the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-laborie-acquired-the-jada-system-for-rapid-postpartum-hemorrhage-control-expanding-obstetrics-portfolio-nbsp\"><span class=\"ez-toc-section\" id=\"Laborie_Acquired_the_JADA%C2%AE_System_for_Rapid_Postpartum_Hemorrhage_Control_Expanding_Obstetrics_Portfolio\"><\/span><strong>Laborie Acquired the JADA\u00ae System for Rapid Postpartum Hemorrhage Control, Expanding Obstetrics Portfolio&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On January 28, 2026, Laborie Medical Technologies Corp (\u201cLaborie\u201d) announced that it had completed the previously announced acquisition of the JADA\u00ae System, marking a significant milestone in the expansion of its obstetrics portfolio. The addition of the JADA System, an FDA-cleared device designed for the rapid control and treatment of abnormal postpartum uterine bleeding, further strengthened Laborie\u2019s commitment to improving the patient journey through innovative solutions that enhance maternal health and safety.<\/p>\n\n\n\n<p>The JADA System became part of Laborie\u2019s comprehensive obstetrics portfolio, which spanned antepartum, intrapartum, postpartum, neonatal, and surgical care. By addressing postpartum hemorrhage (PPH)\u2014one of the most critical complications of childbirth and the leading cause of maternal mortality globally\u2014the device played a key role in tackling an urgent clinical need. Each year, millions of women experience PPH, accounting for more than 20% of all maternal deaths worldwide, underscoring the importance of effective and timely intervention solutions such as the JADA System.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/maternal-mental-health-market\"><strong>Maternal Mental Health Market Report<\/strong><\/a>,\u201d the global maternal mental health market is estimated to grow at a <strong>CAGR of 14.57%<\/strong> during the forecast period from 2024 to 2030. The demand for maternal mental health is primarily being boosted by the growing prevalence of maternal mental health disorders such as postpartum depression, dysthymia, pregnancy-related anxiety, birth-related PTSD (Post-traumatic stress disorder), and others. Furthermore, the growing awareness regarding maternal mental health issues and increasing regulatory approvals for various therapies associated with maternal mental health are also driving the market. Additionally, the growing number of innovations in technology, such as the integration of telehealth, mobile apps, and digital health platforms with maternal mental health solutions, are some of the other key factors that are responsible for contributing to the positive growth of the maternal mental health market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-olympus-announced-u-s-launch-of-the-secureflex-single-use-fine-needle-biopsy-device\"><span class=\"ez-toc-section\" id=\"Olympus_Announced_US_Launch_of_the_SecureFlex%E2%84%A2_Single-Use_Fine_Needle_Biopsy_Device\"><\/span><strong>Olympus Announced U.S. Launch of the SecureFlex\u2122 Single-Use Fine Needle Biopsy Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On January 28, 2026, Olympus Corp. of the Americas announced the U.S. launch of its advanced single-use SecureFlex\u2122 fine needle biopsy (FNB) device, designed for endoscopic ultrasound-guided tissue sampling in the diagnosis of conditions such as pancreatic cancer. The SecureFlex\u2122 FNB needle was developed to collect large, intact tissue samples and to improve access to hard-to-reach lesions, including those in the pancreatic head and uncinate process, and was offered in 19G, 22G, and 25G sizes.<\/p>\n\n\n\n<p>The device featured a Dual-Beveled Raptor\u2122 Tip to support precise tissue acquisition while preserving cellular architecture, along with nitinol construction, a multi-layer sheath for smooth handling, and enhanced ultrasound visibility. Olympus also planned to showcase the SecureFlex FNB needle at major endoscopy meetings, including the Cedars-Sinai Endoscopy Symposium and Orlando Live Endoscopy 2026. The launch supported growing clinical demand for high-quality tissue sampling driven by advances in targeted and immunotherapies for pancreatic cancer and complemented Olympus\u2019 broader GI portfolio, including the EU-ME3 Ultrasound Processor for hepatobiliary and pancreatic procedures.<\/p>\n\n\n\n<p><em>\u201cGastroenterologists require precision and reliability when performing a biopsy for diagnostic accuracy. Olympus is excited to offer U.S. customers a dependable biopsy solution designed for precision sampling,\u201d said Christian Hagie, Vice President, GI EndoTherapy Business Unit Leader, Olympus Corporation of the Americas. \u201cThe SecureFlex EUS-FNB needle offers an advanced design to help physicians perform efficient procedures by facilitating access to complex anatomical structures and obtain adequate samples for diagnostic testing, even in challenging cases.\u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/biopsy-devices-market\"><strong>Biopsy Devices Market Report<\/strong><\/a>\u201d, the global biopsy devices market size is expected to increase from <strong>USD 5,813.16 million<\/strong> in 2024 to <strong>USD 10,812.77 million<\/strong> by 2032, growing at a <strong>CAGR of 8.09%<\/strong> during the forecast period from 2025 to 2032. The market of biopsy devices is being primarily driven by the rising incidence of cancer, such as breast, lung, prostate, and colorectal cancer, among others, increasing demand for minimally invasive procedures, increasing technological advancements in devices, and an increase in product development activities among the key market players.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kardium-announced-publication-of-pulsar-pivotal-trial-results-in-jacc-nbsp\"><span class=\"ez-toc-section\" id=\"Kardium_Announced_Publication_of_PULSAR_Pivotal_Trial_Results_in_JACC\"><\/span><strong>Kardium Announced Publication of PULSAR Pivotal Trial Results in JACC&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On January 21, 2026, Kardium Inc., an emerging leader in advanced solutions for atrial fibrillation, announced that the results of the PULSAR clinical trial had been published in the Journal of the American College of Cardiology (JACC). The landmark study evaluated Kardium\u2019s Globe\u00ae Pulsed Field System for the treatment of paroxysmal atrial fibrillation (PAF).<\/p>\n\n\n\n<p>The multicenter pivotal trial demonstrated that the Globe\u00ae System achieved durable pulmonary vein isolation (PVI) in 95% of treated veins with a single pulsed field application, while maintaining a 0% rate of device-related primary safety events. At 12-month follow-up, 78% of patients remained free from atrial arrhythmias, highlighting the system\u2019s effectiveness in treating drug-refractory PAF.<\/p>\n\n\n\n<p>The study enrolled 183 patients across leading clinical centers in North America and Europe, with procedures showing high efficiency in mapping, ablation, and overall treatment times. Importantly, the trial confirmed the strong safety profile of the technology, reporting a 0% primary device-related safety event rate throughout the study period.<\/p>\n\n\n\n<p><em>\u201cThe Globe Pulsed Field System has the potential to transform how we treat atrial fibrillation by delivering durable pulmonary vein isolation with remarkable efficiency and safety,\u201d said Dr. Vivek Reddy, Principal Investigator of the trial. \u201cThese results show that this technology can make a real difference for patients, offering them better outcomes and a safer path to long\u2011term relief from arrhythmias.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cThe publication of the PULSAR pivotal trial results in JACC is a tremendous validation of the safety, efficacy and efficiency of the Globe System. At Kardium, we are committed to delivering the most advanced system for the treatment of atrial fibrillation,\u201d said Kevin Chaplin, Chief Executive Officer of Kardium.<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/ablation-devices-market\"><strong>Ablation Devices Market Report<\/strong><\/a>,\u201d the global ablation devices market is expected to grow from <strong>USD 8,090.31 million<\/strong> in 2024 to <strong>USD 15,347.69 million <\/strong>by 2032, at a <strong>CAGR of 8.38%<\/strong> during the forecast period from 2025 to 2032. The market for ablation device solutions is primarily driven by the rising prevalence of chronic diseases such as cancer and cardiovascular diseases, as well as by global technological advancements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-patient-treated-in-myra-vision-s-u-s-adapt-clinical-study-for-glaucoma-nbsp\"><span class=\"ez-toc-section\" id=\"First_Patient_Treated_in_Myra_Visions_US_ADAPT_Clinical_Study_for_Glaucoma\"><\/span><strong>First Patient Treated in Myra Vision\u2019s U.S. ADAPT Clinical Study for Glaucoma&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On January 26, 2026, Myra Vision, a Shifamed portfolio company, announced that the first patient had been enrolled in its ADAPT clinical study evaluating the Calibreye\u2122 TGT Surgical System in patients with glaucoma. This milestone marked meaningful progress in the company\u2019s U.S. regulatory pathway, following the FDA\u2019s approval of Myra Vision\u2019s Investigational Device Exemption (IDE) application in August 2025.<\/p>\n\n\n\n<p>The ADAPT trial was designed as a prospective, multicenter, nonrandomized, open-label study and aimed to enroll up to 70 patients with refractory glaucoma, with a 12-month primary effectiveness endpoint. The study assessed the safety and effectiveness of Myra Vision\u2019s titratable glaucoma therapy system, which was developed to optimize intraocular pressure (IOP) reduction in patients undergoing glaucoma surgery. After implantation, the Calibreye\u2122 aqueous shunt was designed to allow slit-lamp\u2013based outflow adjustments, enabling therapy to be tailored over time as individual patient needs evolved.<\/p>\n\n\n\n<p>Glaucoma, the leading cause of irreversible blindness, affected an estimated 80 million people worldwide, and with no cure available, disease management focused on controlling IOP to slow progression. Existing treatment options, including trabeculectomy, tube shunt implants, and newer minimally invasive surgical devices, generally lacked adjustability, highlighting the clinical need addressed by the Calibreye\u2122 system.<\/p>\n\n\n\n<p><em>\u201cWe are thrilled to participate in the ADAPT trial and to have treated our first patient with the Calibreye System,\u201d said Dr. Godfrey. \u201cThe potentially groundbreaking&nbsp; Calibreye System is the first adjustable glaucoma shunt in the United States, aiming to enable clinician-directed postoperative adjustment to support individualized intraocular pressure (IOP) management.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cWe are excited to have enrolled the first patient in our ADAPT clinical study. This is a significant accomplishment for our organization, and an important step towards delivering the Calibreye System to physicians and patients,\u201d commented Robert Chang, President and Chief Executive Officer of Myra Vision. \u201cSubconjunctival filtration procedures like Calibreye are currently being evaluated in a small percentage of eligible moderate to advanced glaucoma patients who require significant pressure reduction. The personalized IOP control provided by Calibreye will offer physicians greater confidence to address the needs of these underserved patients.\u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/micro-invasive-glaucoma-surgery-migs-devices-market\"><strong>Micro Invasive Glaucoma Surgery (MIGS) Devices Market Report<\/strong><\/a>\u201d, the Micro Invasive Glaucoma Surgery (MIGS) Device market was valued at <strong>USD 406.55 million<\/strong> in 2023, growing at a <strong>CAGR of 13.34%<\/strong> during the forecast period from 2024 to 2030 to reach<strong> USD 972.26 million <\/strong>by 2030. The demand for microinvasive glaucoma surgery devices is primarily being boosted by the growing prevalence of glaucoma. Furthermore, the increasing lifestyle disorders such as diabetes and hypertension double the chances of causing glaucoma, leading to vision loss and blindness, thereby boosting the market of micro-invasive glaucoma surgery devices. Additionally, advances in product development, such as greater effectiveness and reduced invasiveness, are key drivers of the positive growth of the micro-invasive glaucoma surgery device market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seno Medical\u2019s Next-Generation Imagio\u00ae Imaging System Obtained European Union (EU) Medical Device Regulation (MDR) CE Mark Certification&nbsp; On January 26, 2026, Seno Medical received CE Mark certification for its next-generation Imagio\u00ae Imaging System, Model 9100, confirming that the device met the stringent safety, performance, and quality requirements set under the EU MDR framework and assessed [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34420,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19675,19875,21807,22862,17021,16975,22217,19823],"industry":[17226],"therapeutic_areas":[17242],"class_list":["post-34418","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ablation-devices","tag-biopsy-devices","tag-diagnostic-imaging-equipment","tag-maternal-mental-health","tag-medical-devices-market","tag-medtech-market","tag-micro-invasive-glaucoma-surgery-devices","tag-spinal-fusion-devices","industry-medical-devices","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Seno Medical, Spine Innovation, Laborie<\/title>\n<meta name=\"description\" content=\"Seno Medical\u2019s Next-Generation Imagio Imaging System; Spine Innovation\u2019s LOGIC Titanium Expandable Interbody System; Olympus\u2019 SecureFlex\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Seno Medical, Spine Innovation, Laborie\" \/>\n<meta property=\"og:description\" content=\"Seno Medical\u2019s Next-Generation Imagio Imaging System; Spine Innovation\u2019s LOGIC Titanium Expandable Interbody System; Olympus\u2019 SecureFlex\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T12:25:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T12:25:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/medtech-news-for-seno-medical-spine-innovation-laborie.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Seno Medical, Spine Innovation, Laborie","description":"Seno Medical\u2019s Next-Generation Imagio Imaging System; Spine Innovation\u2019s LOGIC Titanium Expandable Interbody System; Olympus\u2019 SecureFlex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Seno Medical, Spine Innovation, Laborie","og_description":"Seno Medical\u2019s Next-Generation Imagio Imaging System; Spine Innovation\u2019s LOGIC Titanium Expandable Interbody System; Olympus\u2019 SecureFlex","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-01-29T12:25:46+00:00","article_modified_time":"2026-01-29T12:25:47+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/medtech-news-for-seno-medical-spine-innovation-laborie.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie","name":"MedTech News | Seno Medical, Spine Innovation, Laborie","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/medtech-news-for-seno-medical-spine-innovation-laborie.webp","datePublished":"2026-01-29T12:25:46+00:00","dateModified":"2026-01-29T12:25:47+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Seno Medical\u2019s Next-Generation Imagio Imaging System; Spine Innovation\u2019s LOGIC Titanium Expandable Interbody System; Olympus\u2019 SecureFlex","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seno-medical-spine-innovation-laborie#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/medtech-news-for-seno-medical-spine-innovation-laborie.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/medtech-news-for-seno-medical-spine-innovation-laborie.webp","width":772,"height":482,"caption":"medtech-news-for-seno-medical-spine-innovation-laborie"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/01\/medtech-news-for-seno-medical-spine-innovation-laborie-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ablation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biopsy Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diagnostic Imaging Equipment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Maternal Mental Health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Micro Invasive Glaucoma Surgery Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Fusion Devices<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Ablation Devices<\/span>","<span class=\"advgb-post-tax-term\">Biopsy Devices<\/span>","<span class=\"advgb-post-tax-term\">Diagnostic Imaging Equipment<\/span>","<span class=\"advgb-post-tax-term\">Maternal Mental Health<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Micro Invasive Glaucoma Surgery Devices<\/span>","<span class=\"advgb-post-tax-term\">Spinal Fusion Devices<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 months ago","modified":"Updated 5 months ago"},"absolute_dates":{"created":"Posted on Jan 29, 2026","modified":"Updated on Jan 29, 2026"},"absolute_dates_time":{"created":"Posted on Jan 29, 2026 5:55 pm","modified":"Updated on Jan 29, 2026 5:55 pm"},"featured_img_caption":"medtech-news-for-seno-medical-spine-innovation-laborie","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34418"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34418\/revisions"}],"predecessor-version":[{"id":34419,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34418\/revisions\/34419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34420"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34418"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34418"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}